Pamela Allen, MD
Dermatology · Oklahoma City, OKNPI 1578532503
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,400 of the $7,078 with a category attached, or 62.2%. Pfizer accounts for 88.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $6,326, more than ten times the $271 reported in 2019.
Across 17 payments — averaging $416.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Arcutis Biotherapeutics, Inc.$135
- Therakos LLC$130
- UCB, Inc.$117
- Organogenesis Inc.$114
- Mayne Pharma Commercial LLC$113
- plus $215 from 4 others
What the payments were for
- Consulting fees$4,40062%
- Speaking & faculty fees$2874%
- Travel & lodging$1,37419%
- Food & beverage$97414%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $6,254 |
| Arcutis Biotherapeutics, Inc. | 1 | $135 |
| Therakos LLC | 1 | $130 |
| UCB, Inc. | 1 | $117 |
| Organogenesis Inc. | 1 | $114 |
| Mayne Pharma Commercial LLC | 1 | $113 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Johnson & Johnson | 1 | $43 |
| Lilly USA, LLC | 1 | $41 |
| Novartis | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,078 in reported general payments places this provider in the 65th percentile of 114 dermatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $220,006 |
| Finasteride | 26 | $661 |
| Clobetasol Propionate | 20 | $604 |
| Minoxidil | 13 | $129 |
| Hydroxyzine Hcl | 13 | $58 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Oklahoma City
- Yaohan LamOklahoma City$88K
- Kimberly JerdanOklahoma City$59K
- Mark DawkinsOklahoma City$56K
- Quy PhamOklahoma City$14K
- Sunita CrittendenOklahoma City$13K
- Tiffany BrazealOklahoma City$13K
- Robert LehrOklahoma City$11K
- Courtney CookOklahoma City$10K
- Clifford HendersonOklahoma City$9K
- Roy RindlerOklahoma City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.